Dermatology
Diabetic Skin Care
Diabetes & Dermatology
UltraMIST for Dermatology is a no-contact, low-frequency ultrasound therapy that encourages cellular activation in the face and neck without irritating the skin.
State-of-the-Art
Pain-free, no needles!
Skin revitalization through the power of ultrasonic stimulation
Our non-contact ultrasound treatment has proven to stimulate natural healing
Encourages cellular activation in the face and neck without irritating the skin
BEFORE and AFTER Laser Treatments: Reduces irritation and inflammation caused by laser treatments while providing instant PAIN RELIEF!
Evidence-Based
NOTE: Dermatologists may bill this for non-healing wounds only and is reimbursable by Medicare.
The therapy is administered by trained healthcare personnel to thousands of patients for more than a decade and is supported by a vast array of clinical evidence, the UltraMIST® System’s acoustic wave therapy promotes healing by controlling inflammation and reducing bacteria in the wound bed while increasing angiogenesis. Further, to promote healing, it increases perfusion through vasodilation, ultimately increasing oxygen and nutrients to the tissue.
The UltraMIST® System mechanically removes barriers and promotes healing in a wide range of wound types. Indications include, but are not limited to, diabetic foot ulcers, venous leg ulcers, pressure ulcers, and surgical, burn, and deep tissue injuries. It also reduces and removes a wide range of bacteria, including biofilms, while preserving healthy structures.
By activating the body’s normal regeneration process, the UltraMIST® System offers important wound healing advantages. First, it reduces barriers to healing by reducing bacterial overgrowth, disrupting bacterial biofilms, and controlling inflammation. At the same time, UltraMIST® System therapy promotes healing through vasodilation and by accelerating angiogenesis. A meta-analysis of clinical evidence in cases including diabetic foot, ischemic, neuropathic, venous, multifactorial, pressure, surgical, and traumatic ulcers shows that the rate of wound closure increased from 24% with standard care to 42% with UltraMIST® use over a 12-week interval.
To accelerate wound healing even more, in between the UltraMIST® System treatments, other standard or advanced wound therapies may be incorporated into the treatment plan — at the discretion of the wound care professional. The result? Faster relief and better quality of life for your patients with less expenditure of time and resources on costly treatments that don’t work. These savings make the UltraMIST® System a financially viable solution for the patient, the provider, and the healthcare system as a whole.
Medicare Coverage Guidance for UltraMIST®
Low-frequency, non-contact, non-thermal ultrasound (MIST Therapy) will be considered reasonable and necessary wound therapy and therefore eligible for coverage by Medicare when provided for any of the following clinical conditions:
Wounds and ulcers which are too painful for sharp or excisional debridement and have failed conventional debridement with documentation supporting the same.
Wounds and ulcers meeting Medicare coverage for debridement but with documented contraindications to sharp or excisional debridement.
Wounds and ulcers meeting Medicare coverage for debridement but with documented evidence of no signs of improvement after 30 days of standard wound care.
Coverage for Low Frequency, non-contact, non-thermal ultrasound is as follows:
Low-frequency, non-contact, non-thermal ultrasound (MIST Therapy) must be provided two (2) to three (3) times per week to be considered reasonable and necessary. The length of individual treatments will vary per wound size.
Observable, documented improvements in the wound(s) should be evident after six (6) treatments. Improvements include documented reduction in pain, necrotic tissue, wound size; or improved granulation tissue. Continuing treatments for wounds demonstrating no improvement after six (6) treatments is considered not reasonable and necessary.
No more than eighteen (18) treatments within a six-week period will be considered reasonable and necessary. This type of therapy is included in the payment for the treatment of the same wound with other active wound care management or wound debridement. Low frequency, non-contact, non-thermal ultrasound treatments would be separately billable if other active wound management and/or wound debridement is not performed.
This type of therapy is included in the payment for the treatment of the same wound with other active wound care management or wound debridement. Low frequency, non-contact, non-thermal ultrasound treatments would be separately billable if other active wound management and/or wound debridement is not performed.
Improvements may include documented reduction in pain, necrotic tissue, wound size; or improved granulation tissue.
